Drug Profile
Research programme: antibody cancer therapeutics - Invenra/Oxford BioTherapeutics
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Invenra; Oxford BioTherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 25 Jun 2015 Invenra and Oxford BioTherapeutuics enter into a collaboration for the research and development of monoclonal-antibodies for Cancer
- 25 Jun 2015 Early research in Cancer in USA (Parenteral) after June 2015